Literature DB >> 11145232

Oral delivery of new heparin derivatives in rats.

Y Lee1, S H Kim, Y Byun.   

Abstract

PURPOSE: In this study, conjugates of heparin and deoxycholic acid were synthesized in order to enhance the heparin absorption in the GI tract. Oral delivery of heparin is a preferred therapy in the treatment of patients who are at high risk of deep vein thrombosis and pulmonary embolism.
METHODS: Several different kinds of heparin derivatives were synthesized, and their absorption in the GI tract was determined by activated partial thromboplastin time (aPTT) and factor Xa (FXa) assay. Any histological changes caused by heparin derivatives were examined by hematoxylin and eosin (H&E) stain and transmission electron microscopy (TEM).
RESULTS: After administering heparin-DOCA orally, the clotting time in aPTT assay was increased with the increase of the coupled DOCA amount. The maximum clotting time of heparin-DOCA was 136+/-33 sec at 200 mg/kg of oral dose. This value was 7 times higher than the baseline. The absorption of heparin-cholesterol, heparin-palmitic acid, and heparin-lauric acid conjugates in the GI tract was lower than that of heparin-DOCA. Histological examination of the GI tract indicated that heparin derivatives did not cause any damage to the microvilli and the cell layer.
CONCLUSIONS: DOCA coupled with heparin greatly enhanced absorption of heparin in the GI tract, and this enhancing effect was induced without changing the tissue structure of the GI wall.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145232     DOI: 10.1023/a:1026474919869

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

Review 1.  The development of delivery agents that facilitate the oral absorption of macromolecular drugs.

Authors:  A Leone-Bay; D R Paton; J J Weidner
Journal:  Med Res Rev       Date:  2000-03       Impact factor: 12.944

2.  Intraduodenal absorption of the new UF-heparin salt ITF 1057 in the conscious dog.

Authors:  I Caramazza; G D'Atri; M L Bossi; F De Ponti; L D'Angelo; A Crema
Journal:  Thromb Res       Date:  1991-06-15       Impact factor: 3.944

Review 3.  Low-molecular-weight heparin for the treatment of deep vein thrombosis.

Authors:  J K Thompson-Ford
Journal:  Pharmacotherapy       Date:  1998 Jul-Aug       Impact factor: 4.705

4.  Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations.

Authors:  T M Rivera; A Leone-Bay; D R Paton; H R Leipold; R A Baughman
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

Review 5.  Biochemistry and pharmacology of low molecular weight heparin.

Authors:  R D Rosenberg
Journal:  Semin Hematol       Date:  1997-10       Impact factor: 3.851

6.  New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds.

Authors:  A Dal Pozzo; M Acquasaliente; M R Geron; G Andriuoli
Journal:  Thromb Res       Date:  1989-10-01       Impact factor: 3.944

7.  Anticoagulant action of heparin.

Authors:  P S Damus; M Hicks; R D Rosenberg
Journal:  Nature       Date:  1973-12-07       Impact factor: 49.962

8.  Effects of acidity, cations and alcoholic fractionation on absorption of heparin from gastrointestinal tract.

Authors:  T K Sue; L B Jaques; E Yuen
Journal:  Can J Physiol Pharmacol       Date:  1976-08       Impact factor: 2.273

9.  Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation.

Authors:  Y Lee; H T Moon; Y Byun
Journal:  Thromb Res       Date:  1998-11-15       Impact factor: 3.944

Review 10.  Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations.

Authors:  G F Pineo; R D Hull
Journal:  Med Clin North Am       Date:  1998-05       Impact factor: 5.456

View more
  5 in total

1.  A new drug carrier, Nalpha-deoxycholyl-L: -lysyl-methylester, for enhancing insulin absorption in the intestine.

Authors:  S Lee; J Lee; D Y Lee; S K Kim; Y Lee; Y Byun
Journal:  Diabetologia       Date:  2005-03-01       Impact factor: 10.122

Review 2.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

3.  Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.

Authors:  Yiwei Qi; Ganlin Zhao; Dongfang Liu; Zachary Shriver; Mallik Sundaram; Shiladitya Sengupta; Ganesh Venkataraman; Robert Langer; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-29       Impact factor: 11.205

4.  Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil.

Authors:  Constantia E Kast; Davide Guggi; Nina Langoth; Andreas Bernkop-Schnürch
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

Review 5.  Strategies to Overcome Heparins' Low Oral Bioavailability.

Authors:  Ana Rita Neves; Marta Correia-da-Silva; Emília Sousa; Madalena Pinto
Journal:  Pharmaceuticals (Basel)       Date:  2016-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.